lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

672

PubMed (Gene Name)

Literature evidence

17289874 (BRCA1)

low mRNA and protein expression in the BRCA1/BRCA2 and XRCC5 genes occur in lung adenocarcinoma and squamous cell carcinoma, respectively, and promoter hypermethylation is the predominant mechanism in deregulation of these genes

19073515 (BRCA1)

report provides a review on BRCA1, a promising gene determinant of response to different types of chemotherapy and its potential applications as a new molecular marker in lung cancer [review]

19289372 (BRCA1)

High BRCA1 mRNA expression confers poor prognosis in early non-small-cell lung cancer, and the combination of high BRCA1 and low XPG expression still further increases the risk of shorter survival

20467918 (BRCA1)

ERCC1, RRM1 and BRCA1 are promising predictive and prognostic biomarkers in advanced non-small cell lung cancer.

21781528 (BRCA1)

The expression level of BRCA1 and class IIIbeta-tubulin in tumor tissue is probably a predictor for the efficacy of chemotherapy in non-small cell lung cancer patients.

22093627 (BRCA1)

FISH-positive EGFR expression is associated with gender and smoking status, but not correlated with the expression of ERCC1 and BRCA1 proteins in non-small cell lung cancer.

22901997 (BRCA1)

BRCA1 as a new predictive marker for chemotherapy and radiotherapy of non-small cell lung cancer

23335114 (BRCA1)

Methylation of breast cancer susceptibility gene 1 (BRCA1) predicts recurrence in patients with curatively resected stage I non-small cell lung cancer.

23407556 (BRCA1)

High BRCA1 mRNA levels were associated with response to erlotinib in non-small-cell lung cancer.

23803067 (BRCA1)

High BRCA1 expression is associated with non-small cell lung cancer.

24443257 (BRCA1)

Our results suggest that ERCC1 and BRCA1 mRNA expressions are associated with progression-free survival and overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

26740498 (BRCA1)

treatment response, survival, and the associations between KRAS mutation status and tumour expression levels of BRCA1, TYMS and SRC retrospectively in a cohort of patients with non-small cell lung cancer, were evaluated.

28358361 (BRCA1)

tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines

28373435 (BRCA1)

High BRCA1 expression is associated with lung Adenocarcinoma.

33030583 (BRCA1)

Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.